Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARVNNASDAQ:FDMTNASDAQ:IMTXNASDAQ:QURE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$7.58+2.4%$12.10$5.94▼$37.38$521.29M2.31.09 million shs2.30 million shsFDMT4D Molecular Therapeutics$3.10+11.5%$3.90$2.24▼$28.93$143.54M2.89830,197 shs854,391 shsIMTXImmatics$4.37+3.3%$4.54$3.30▼$13.77$531.17M0.85651,368 shs379,497 shsQUREuniQure$9.65+5.2%$12.01$3.73▼$19.18$521.84M0.421.68 million shs796,057 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas+2.43%+22.46%-10.08%-57.25%-78.17%FDMT4D Molecular Therapeutics+11.51%+23.51%-24.57%-38.49%-88.19%IMTXImmatics+3.31%+24.15%-3.96%-24.00%-57.98%QUREuniQure+5.23%+15.71%-32.04%-31.02%+103.59%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARVNArvinas3.7101 of 5 stars4.34.00.00.02.02.51.3FDMT4D Molecular Therapeutics2.584 of 5 stars4.31.00.00.02.61.70.6IMTXImmatics2.3368 of 5 stars3.63.00.00.03.01.70.0QUREuniQure2.1775 of 5 stars3.42.00.00.01.92.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARVNArvinas 2.69Moderate Buy$34.53355.58% UpsideFDMT4D Molecular Therapeutics 2.50Moderate Buy$26.71761.75% UpsideIMTXImmatics 3.20Buy$16.67281.39% UpsideQUREuniQure 2.82Moderate Buy$38.80302.07% UpsideCurrent Analyst Ratings BreakdownLatest FDMT, IMTX, ARVN, and QURE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2025ARVNArvinasTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$65.00 ➝ $21.004/8/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (D-)4/7/2025ARVNArvinasHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$81.00 ➝ $81.004/1/2025IMTXImmaticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight4/1/2025QUREuniQureChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$27.00 ➝ $38.003/22/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (E+)3/13/2025ARVNArvinasMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$48.00 ➝ $12.003/13/2025ARVNArvinasGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$57.00 ➝ $32.003/13/2025ARVNArvinasThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$70.00 ➝ $15.003/12/2025ARVNArvinasBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$82.00 ➝ $20.003/12/2025ARVNArvinasWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOverweight ➝ Overweight$60.00 ➝ $26.00(Data available from 4/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARVNArvinas$263.40M1.98N/AN/A$8.17 per share0.93FDMT4D Molecular Therapeutics$37K3,879.36N/AN/A$7.20 per share0.43IMTXImmatics$155.84M3.41N/AN/A$2.88 per share1.52QUREuniQure$27.12M19.24N/AN/A$4.34 per share2.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARVNArvinas-$198.90M-$2.77N/AN/AN/A-75.51%-33.75%-16.75%5/6/2025 (Estimated)FDMT4D Molecular Therapeutics-$100.84M-$2.98N/AN/AN/AN/A-28.00%-26.16%5/8/2025 (Estimated)IMTXImmatics-$104.98M$0.14N/AN/AN/A-47.94%-15.90%-9.38%5/13/2025 (Estimated)QUREuniQure-$308.48M-$4.93N/AN/AN/A-837.80%-188.82%-32.17%5/6/2025 (Estimated)Latest FDMT, IMTX, ARVN, and QURE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025IMTXImmatics-$0.39N/AN/AN/A$14.92 millionN/A5/8/2025Q1 2025FDMT4D Molecular Therapeutics-$0.84N/AN/AN/A$0.53 millionN/A5/6/2025Q1 2025ARVNArvinas-$0.93N/AN/AN/A$41.87 millionN/A5/6/2025Q1 2025QUREuniQure-$1.07N/AN/AN/AN/AN/A3/27/2025Q4 2024IMTXImmatics-$0.03$0.48+$0.51$0.48$16.16 million$15.67 million2/28/2025Q4 2024FDMT4D Molecular Therapeutics-$0.80-$0.90-$0.10-$0.90$2.28 millionN/A2/11/2025Q4 2024ARVNArvinas-$1.07-$0.63+$0.44-$0.63$62.79 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARVNArvinasN/AN/AN/AN/AN/AFDMT4D Molecular TherapeuticsN/AN/AN/AN/AN/AIMTXImmaticsN/AN/AN/AN/AN/AQUREuniQureN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARVNArvinasN/A4.644.64FDMT4D Molecular TherapeuticsN/A17.3317.33IMTXImmaticsN/A3.983.98QUREuniQure0.926.516.51Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARVNArvinas95.19%FDMT4D Molecular Therapeutics99.27%IMTXImmatics64.41%QUREuniQure78.83%Insider OwnershipCompanyInsider OwnershipARVNArvinas5.23%FDMT4D Molecular Therapeutics7.30%IMTXImmatics3.30%QUREuniQure4.74%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARVNArvinas42068.77 million65.18 millionOptionableFDMT4D Molecular Therapeutics12046.30 million42.85 millionOptionableIMTXImmatics260121.55 million115.42 millionOptionableQUREuniQure50054.08 million46.43 millionOptionableFDMT, IMTX, ARVN, and QURE HeadlinesRecent News About These CompaniesUniQure (QURE) Reports Q4 Loss, Misses Revenue EstimatesFebruary 27, 2025 | zacks.comuniQure Announces 2024 Financial Results and Highlights Recent Company ProgressFebruary 27, 2025 | globenewswire.comuniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four YearsFebruary 7, 2025 | benzinga.comCSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia BFebruary 7, 2025 | prnewswire.comuniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry DiseaseFebruary 3, 2025 | globenewswire.comuniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALSJanuary 30, 2025 | globenewswire.comuniQure Announces Pricing of its Public OfferingJanuary 8, 2025 | globenewswire.comuniQure Announces Proposed Public OfferingJanuary 7, 2025 | globenewswire.comUp 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025?December 15, 2024 | fool.comQURE Soars on FDA Alignment for Speedy Approval of Huntington's DrugDecember 11, 2024 | zacks.comuniQure's AMT-130: A Bold Step For Huntington's, But Not Without HurdlesDecember 10, 2024 | seekingalpha.comuniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's DiseaseDecember 10, 2024 | globenewswire.comWall Street Analysts Think uniQure (QURE) Could Surge 228.07%: Read This Before Placing a BetNovember 29, 2024 | zacks.comWhat Makes uniQure (QURE) a New Buy StockNovember 28, 2024 | zacks.comuniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe EpilepsyNovember 21, 2024 | globenewswire.comWall Street Analysts Believe uniQure (QURE) Could Rally 169.18%: Here's is How to TradeNovember 8, 2024 | zacks.comUniQure (QURE) Reports Q3 Loss, Lags Revenue EstimatesNovember 5, 2024 | zacks.comuniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company ProgressNovember 5, 2024 | globenewswire.comUniQure (QURE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseOctober 29, 2024 | zacks.comuniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALSOctober 15, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFDMT, IMTX, ARVN, and QURE Company DescriptionsArvinas NASDAQ:ARVN$7.58 +0.18 (+2.43%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$7.34 -0.24 (-3.10%) As of 04:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.4D Molecular Therapeutics NASDAQ:FDMT$3.10 +0.32 (+11.51%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$3.08 -0.02 (-0.81%) As of 04/15/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.Immatics NASDAQ:IMTX$4.37 +0.14 (+3.31%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$4.37 0.00 (0.00%) As of 04/15/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.uniQure NASDAQ:QURE$9.65 +0.48 (+5.23%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$9.65 0.00 (0.00%) As of 04:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike Stock is a Buy as Cyberthreat Environment Expands Congress! Who Traded What During the Tariff-Induced Meltdown Beware of BigBear.ai: Insiders Are Selling—Should You? NATO Deal Sparks 4% Jump in Palantir Stock—What’s Next? Microsoft: A Blend of Growth and Value Amid Tariff Concerns Why NVIDIA Stock Could Soar Despite Wall Street Downgrades Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold Don’t Fear, New Highs for Fastenal Will Soon Be Here Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
